There's a big garbage pile of drugs that look promising in phase I and fail in II or III. It will take 1-2 years before we/ARNA know with more certainty if the drug works, and is commercially viable, in which indications it works, dose, combo, or not...
what about 289? When DJ first introduced 289 you would have thought is cured every cancer. Maybe he was listening to the wrong people and just doesn't know any better, but he's the CEO and he has zero credibility now with shareholders and the street. If DJ and the BOD are not buying stock at this level, they need to sell and get out, or just get out.
also, not everyone that orders a test will send it back, there is always some loss. I think they put this PR out in response to the analyst model info that someone posted. This management team is very savvy.
On the + side, someone is still investing in ADC's. On the - side, they did not invest in IMGN's technology. IMGN has $100MM is cash, they will need more cash within the year. Shareholders have no interest in a secondary, I hope they get this, but doubt it. 853 and 529 seem marginal. The BOD needs to get off their #$%$'s and communicate the strategy for getting the stock price up NOW. Firing Junius, hiring Pien and stating the company will be reorganized and all options are on the table is the only way IMO. 289 might get some cash interest if they can ever show some human clinical date.
no company will pay$15+ for a stock trading below $6. Stock price will have to get to at least $9-10 before that would happen. I am hoping price goes back to $5 first, so I don't lose all of my stock. I will not chase this stock higher, it only breaks my heart and bank account.
It takes time to roll out a new product. Long term investors should check back in a year. Traders can also make money trading the technicals, but you have to sell high to buy low. Shorts are toast and should admit their mistake and cover ASAP.
yes, one had options set to expire, one did not and for expiring options it was a no-brainer. Either way, a good selling opportunity in hind sight. I sold some (small amount) and many calls (a little early). Who would have dreamed phase I data would send the stock up that much?
It's my understanding Eisai are planning to do some marketing research first to verify physician interest in a lower side effect, lower efficacy product, which is what Belviq would be. MR takes a little time, I don't think they will make a decision on smoking immediately. IMO, not advice.
How convenient. Management lets shareholders twist in the wind with no PR for months than, just before expiration they crank up the PR machine. My trust level is very low. Obviously they are not selling the company, we can take that off the table and so will shorts. New shorts are probably piling in here.
I sold some calls today. Unless they get acquired, I don't expect a fast ramp in sales. I am frequently wrong, so don't listen to me! Shorts do need to buy a lot of shares.
I take Humira, don't think it will be replicated for a few years and even then bio-similar will be expensive. Remicade is hospital infusion. There are a few new drugs, they are all very expensive. An oral drug, if successful would be a huge seller, but ARNA is at lease 3-4 years from approval.
you are all over the map, CEO should retire, now it's a buy out. I think you are boiler room owner HomerunBcl2, he also loved near Philly. He claimed to have a "big group" of owners in Genta, but was just a short tool.
borrow, are you kidding? They tried that in the past and DF ate their lunch. Borrowing for money-burning biotech's is a terrible strategy. It's either partner for cash, sell out, or secondary (at some point). Burn is not sustainable. I have talked to people at Eisai, they are very conservative and don't seem to have a clear strategy for growth of Belviq into new areas just yet. It could happen, but forget Nash, maybe smoking, but they don't seem to be thrilled with the results.
shocking price and volume action. If they are not in the process of selling the company, they will have to consider issuing some shares at this price.
Lots of options at the $5 level, I was expecting gravity to take it there. Maybe I was wishing since I sold $5 calls yesterday (a little early). Volume was and still is amazing. Not sure what to do with this crazy stock, I wish I had faith to hold. Maybe I will just be an ARNA trader in the future if I lose my stock at $5.